Selected research
Industry Research
Treating Chronic Myeloid Leukemia by Phase Industry Research Report 2026
Market perspective
The global Treating Chronic Myeloid Leukemia by Phase market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Treating Chronic Myeloid Leukemia by Phase market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Treating Chronic Myeloid Leukemia by Phase market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Treating Chronic Myeloid Leukemia by Phase market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Treating Chronic Myeloid Leukemia by Phase include Chia Tai Tianqing Pharmaceutical, Suzhou Thery Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lunan Pharmaceutical, Hansoh Pharmaceutical, Teva, Takeda Pharmaceuticals and Sun Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Treating Chronic Myeloid Leukemia by Phase market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Treating Chronic Myeloid Leukemia by Phase.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Treating Chronic Myeloid Leukemia by Phase Market by Company
Chia Tai Tianqing Pharmaceutical
Suzhou Thery Pharmaceutical
CSPC Ouyi Pharmaceutical
Qilu Pharmaceutical
Lunan Pharmaceutical
Hansoh Pharmaceutical
Teva
Takeda Pharmaceuticals
Sun Pharmaceuticals
Sawai Pharmaceutical
Pfizer
Novartis
Mylan
Lupin
Hetero
Eugia Pharma
Dr. Reddy's Laboratories
Bristol Myers Squibb
Apotex
Treating Chronic Myeloid Leukemia by Phase Segment by Type
Blast Phase
Accelerated Phase
Chronic Phase
Treating Chronic Myeloid Leukemia by Phase Segment by Application
Hospitals
Clinics
Others
Treating Chronic Myeloid Leukemia by Phase Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treating Chronic Myeloid Leukemia by Phase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Treating Chronic Myeloid Leukemia by Phase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treating Chronic Myeloid Leukemia by Phase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Treating Chronic Myeloid Leukemia by Phase companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blast Phase
- Accelerated Phase
- Chronic Phase
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Chia Tai Tianqing Pharmaceutical
- Suzhou Thery Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Qilu Pharmaceutical
- Lunan Pharmaceutical
- Hansoh Pharmaceutical
- Teva
- Takeda Pharmaceuticals
- Sun Pharmaceuticals
- Sawai Pharmaceutical
- Pfizer
- Novartis
- Mylan
- Lupin
- Hetero
- Eugia Pharma
- Dr. Reddy's Laboratories
- Bristol Myers Squibb
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Treating Chronic Myeloid Leukemia by Phase by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Blast Phase
- 2.2.3 Accelerated Phase
- 2.2.4 Chronic Phase
- 2.3 Treating Chronic Myeloid Leukemia by Phase by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Type
- 3.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Type (2021-2026)
- 3.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2027-2032)
4 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Application
- 4.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Application (2021-2026)
- 4.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Treating Chronic Myeloid Leukemia by Phase Market Perspective (2021-2032)
- 5.2 Global Treating Chronic Myeloid Leukemia by Phase Growth Trends by Region
- 5.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Region (2021-2026)
- 5.2.3 Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2027-2032)
- 5.3 Treating Chronic Myeloid Leukemia by Phase Market Dynamics
- 5.3.1 Treating Chronic Myeloid Leukemia by Phase Industry Trends
- 5.3.2 Treating Chronic Myeloid Leukemia by Phase Market Drivers
- 5.3.3 Treating Chronic Myeloid Leukemia by Phase Market Challenges
- 5.3.4 Treating Chronic Myeloid Leukemia by Phase Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue
- 6.1.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue (2021-2026)
- 6.1.2 Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Players (2021-2026)
- 6.2 Global Treating Chronic Myeloid Leukemia by Phase Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Treating Chronic Myeloid Leukemia by Phase Head Office and Area Served
- 6.4 Global Treating Chronic Myeloid Leukemia by Phase Players, Product Type & Application
- 6.5 Global Treating Chronic Myeloid Leukemia by Phase Manufacturers Established Date
- 6.6 Global Treating Chronic Myeloid Leukemia by Phase Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 7.2 North America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 7.4 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 8.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 8.4 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 9.2 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 10.2 South America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 10.4 South America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 11.2 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Chia Tai Tianqing Pharmaceutical
- 12.1.1 Chia Tai Tianqing Pharmaceutical Company Information
- 12.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 12.1.3 Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.1.4 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
- 12.2 Suzhou Thery Pharmaceutical
- 12.2.1 Suzhou Thery Pharmaceutical Company Information
- 12.2.2 Suzhou Thery Pharmaceutical Business Overview
- 12.2.3 Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.2.4 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.2.5 Suzhou Thery Pharmaceutical Recent Developments
- 12.3 CSPC Ouyi Pharmaceutical
- 12.3.1 CSPC Ouyi Pharmaceutical Company Information
- 12.3.2 CSPC Ouyi Pharmaceutical Business Overview
- 12.3.3 CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.3.4 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.3.5 CSPC Ouyi Pharmaceutical Recent Developments
- 12.4 Qilu Pharmaceutical
- 12.4.1 Qilu Pharmaceutical Company Information
- 12.4.2 Qilu Pharmaceutical Business Overview
- 12.4.3 Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.4.4 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.4.5 Qilu Pharmaceutical Recent Developments
- 12.5 Lunan Pharmaceutical
- 12.5.1 Lunan Pharmaceutical Company Information
- 12.5.2 Lunan Pharmaceutical Business Overview
- 12.5.3 Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.5.4 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.5.5 Lunan Pharmaceutical Recent Developments
- 12.6 Hansoh Pharmaceutical
- 12.6.1 Hansoh Pharmaceutical Company Information
- 12.6.2 Hansoh Pharmaceutical Business Overview
- 12.6.3 Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.6.4 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.6.5 Hansoh Pharmaceutical Recent Developments
- 12.7 Teva
- 12.7.1 Teva Company Information
- 12.7.2 Teva Business Overview
- 12.7.3 Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.7.4 Teva Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.7.5 Teva Recent Developments
- 12.8 Takeda Pharmaceuticals
- 12.8.1 Takeda Pharmaceuticals Company Information
- 12.8.2 Takeda Pharmaceuticals Business Overview
- 12.8.3 Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.8.4 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.8.5 Takeda Pharmaceuticals Recent Developments
- 12.9 Sun Pharmaceuticals
- 12.9.1 Sun Pharmaceuticals Company Information
- 12.9.2 Sun Pharmaceuticals Business Overview
- 12.9.3 Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.9.4 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.9.5 Sun Pharmaceuticals Recent Developments
- 12.10 Sawai Pharmaceutical
- 12.10.1 Sawai Pharmaceutical Company Information
- 12.10.2 Sawai Pharmaceutical Business Overview
- 12.10.3 Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.10.4 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.10.5 Sawai Pharmaceutical Recent Developments
- 12.11 Pfizer
- 12.11.1 Pfizer Company Information
- 12.11.2 Pfizer Business Overview
- 12.11.3 Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.11.4 Pfizer Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.11.5 Pfizer Recent Developments
- 12.12 Novartis
- 12.12.1 Novartis Company Information
- 12.12.2 Novartis Business Overview
- 12.12.3 Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.12.4 Novartis Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.12.5 Novartis Recent Developments
- 12.13 Mylan
- 12.13.1 Mylan Company Information
- 12.13.2 Mylan Business Overview
- 12.13.3 Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.13.4 Mylan Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.13.5 Mylan Recent Developments
- 12.14 Lupin
- 12.14.1 Lupin Company Information
- 12.14.2 Lupin Business Overview
- 12.14.3 Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.14.4 Lupin Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.14.5 Lupin Recent Developments
- 12.15 Hetero
- 12.15.1 Hetero Company Information
- 12.15.2 Hetero Business Overview
- 12.15.3 Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.15.4 Hetero Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.15.5 Hetero Recent Developments
- 12.16 Eugia Pharma
- 12.16.1 Eugia Pharma Company Information
- 12.16.2 Eugia Pharma Business Overview
- 12.16.3 Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.16.4 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.16.5 Eugia Pharma Recent Developments
- 12.17 Dr. Reddy's Laboratories
- 12.17.1 Dr. Reddy's Laboratories Company Information
- 12.17.2 Dr. Reddy's Laboratories Business Overview
- 12.17.3 Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.17.4 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.17.5 Dr. Reddy's Laboratories Recent Developments
- 12.18 Bristol Myers Squibb
- 12.18.1 Bristol Myers Squibb Company Information
- 12.18.2 Bristol Myers Squibb Business Overview
- 12.18.3 Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.18.4 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.18.5 Bristol Myers Squibb Recent Developments
- 12.19 Apotex
- 12.19.1 Apotex Company Information
- 12.19.2 Apotex Business Overview
- 12.19.3 Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- 12.19.4 Apotex Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- 12.19.5 Apotex Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst